IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Previously Presented): A method for selectively inhibiting the C-terminal site of angiotensin I converting enzyme comprising administering to a patient in need thereof at least one phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I) below:




(I)

wherein,

- $R_2$ and $R_3$, which are identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro (proline) residue, and

- $R_5$ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 2 (Previously Presented): A method for selectively inhibiting the C-terminal site of angiotensin I converting enzyme comprising administering to a patient in need thereof a phosphinic pseudopeptide derivative corresponding to formula (II) below:




(II)

wherein,

- $R_1$ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,

- $R_2$ and $R_3$, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro residue,

- $R_4$ represents a hydrogen atom or a pharmacologically acceptable counterion, and

- $R_5$ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 3 (Previously Presented): The method of Claim 2, wherein $R_1$ represents a protecting group for an amine function chosen from acetyl and benzyloxycarbonyl groups.

Claim 4 (Previously Presented): The method of Claim 1, wherein $R_2$ represents the benzyl, methyl or phenylethyl group.

Claim 5 (Previously Presented): The method of Claim 1, wherein $R_3$ represents the side chain of alanine, arginine or tryptophan.

Claim 6 (Previously Presented): The method of Claim 1, wherein the sequence –NH-$CH(R_3)$-CO- forms the Pro residue:




Claim 7 (Currently Amended): The method of Claim 1, wherein ~~$R_4$ and/or~~ $R_5$ represent(s) a hydrogen atom.

Claim 8 (Previously Presented): The method of Claim 2, wherein the phosphinic pseudopeptide derivative is:




(pseudo-peptide G)

Claim 9 (Previously Presented): A phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I):




(I)

wherein,

- $R_2$ represents the side chain of a natural or unnatural amino acid,
- the sequence:




forms the Pro residue:




and

- $R_5$ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 10 (Previously Presented): A phosphinic pseudopeptide derivative of formula (II):




(II)

wherein,

- $R_1$ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- $R_2$ represents the side chain of a natural or unnatural amino acid,
- the sequence:




forms the Pro residue:




- $R_4$ represents a hydrogen atom or a pharmacologically acceptable counterion, and
- $R_5$ represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 11 (Previously Presented): A phosphinic pseudopeptide derivative of formula:




(pseudo-peptide G)

Claim 12 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 9.

Claim 13 (Previously Presented): A pharmaceutical composition, comprising a phosphinic pseudopeptide derivative of formula:



(pseudo-peptide G)

Claim 14 (Previously Presented): A process for preparing a pseudopeptide of formula:



(II)

wherein:

- $R_1$ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- $R_2$ and $R_3$, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro residue, and

- $R_4$ and $R_5$ represent a hydrogen atom;

which comprises the following steps:

1) reacting a compound of formula (III):




(III)

in which $R_1$ and $R_2$ are as defined above, with the compound of formula (IV):




(IV)

in which Ac represents the acetyl group and Et represents the ethyl group, to obtain the compound of formula (V):




(V)

2) converting compound (V) into compound (VI) by reacting compound (V) with sodium borohydride:




(VI)

3) protecting the hydroxyl group of compound (VI) with a protecting group $R_5$ to give the compound of formula (VII):




(VII)

4) saponifying compound (VII) to give the compound of formula (VIII):




(VIII)

5) coupling the compound of formula (VIII) with the amino acid of formula (IX) or (X):




(IX)

or




(X)

in which $R_3$ is as defined above, and

6) removing the protecting group $R^5$.

Claim 15 (Previously Presented): A process as claimed in Claim 14, wherein the peptide coupling step 5) is performed via solid-phase peptide synthesis wherein the solid phase is a resin substituted with the amino acid of formula (IX) or (X).

Claim 16 (Previously Presented): A process for preparing a pseudopeptide of formula:




(II)

wherein,

- $R_1$ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- $R_2$ and $R_3$, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro residue,

- $R_4$ represents a hydrogen atom, and
- $R_5$ represents a group that forms an *in vivo* hydrolysable phosphinic ester;

wherein the phosphinic function of the pseudopeptide obtained via the process of Claim 14 is esterified by coupling with an alcohol of formula $R_5OH$ or by reaction with a halide of formula $R_5X$ in which X represents a halogen atom.

Claim 17 (Previously Presented): A compound of formula (VIII):




(VIII)

wherein:

- Ad represents an adamantyl group,

- $R_1$ represents a protecting group for an amine function or an amino acid or a peptide protected with an amine function, and

- $R_2$ represents the side chain of a natural or unnatural amino acid.

Claim 18 (Previously Presented): The method of Claim 2, wherein $R_2$ represents the benzyl, methyl or phenylethyl group.

Claim 19 (Previously Presented): The method of Claim 2, wherein $R_3$ represents the side chain of alanine, arginine or tryptophan.

Claim 20 (Previously Presented): The method of Claim 2, wherein the sequence – NH-CH($R_3$)-CO- forms the Pro residue:




Claim 21 (Previously Presented): The method of Claim 2, wherein $R_4$ and/or $R_5$ represent(s) a hydrogen atom.

Claim 22 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 10.

Claim 23 (Previously Presented): A pharmaceutical composition comprising at least one phosphinic pseudopeptide derivative as claimed in Claim 11.

Claim 24 (Previously Presented): A process for preparing a pseudopeptide of formula:




(II)

wherein,

- $R_1$ represents a protecting group for an amine function, or an amino acid or a peptide protected with a protecting group for an amine function,
- $R_2$ and $R_3$, which may be identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:




also possibly forming the Pro residue,

- $R_4$ represents a hydrogen atom, and
- $R_5$ represents a group that forms an *in vivo* hydrolysable phosphinic ester;

wherein the phosphinic function of the pseudopeptide obtained via the process of Claim 15 is esterified by coupling with an alcohol of formula $R_5OH$ or by reaction with a halide of formula $R_5X$ in which X represents a halogen atom.

Claim 25 (Previously Presented): A process as claimed in Claim 14, wherein $R^5$ is an adamantly group.